

Rachel F Tyndale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7801886/publications.pdf>

Version: 2024-02-01

360
papers

17,617
citations

13865

67
h-index

23533

111
g-index

365
all docs

365
docs citations

365
times ranked

14068
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe. <i>Nicotine and Tobacco Research</i> , 2023, 25, 120-126.	2.6	3
2	Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures. <i>Nicotine and Tobacco Research</i> , 2022, 24, 270-274.	2.6	4
3	Functional characterization of novel rare <i>CYP2A6</i> variants and potential implications for clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 204-220.	3.1	8
4	Does sex alter the relationship between <i>CYP2B6</i> variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. <i>Addiction</i> , 2022, 117, 1715-1724.	3.3	3
5	Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia. <i>Biochemical Pharmacology</i> , 2022, 198, 114949.	4.4	7
6	Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. <i>Pharmacogenetics and Genomics</i> , 2022, Publish Ahead of Print, .	1.5	1
7	Examining the role of mitochondrial genetic variation in nicotine dependence. <i>Psychiatry Research</i> , 2022, 310, 114452.	3.3	0
8	Does genetic variation in a bitter taste receptor gene alter early smoking behaviours in adolescents and young adults?. <i>Addiction</i> , 2022, , .	3.3	0
9	Brief Report: Nicotine Metabolism Ratio Increases in HIV-Positive Smokers on Effective Antiretroviral Therapy: A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 428-432.	2.1	3
10	Fatty acid amide hydrolase levels in brain linked with threat-related amygdala activation. <i>NeuroImage Reports</i> , 2022, 2, 100094.	1.0	1
11	Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. <i>Advances in Pharmacology</i> , 2022, , 73-106.	2.0	4
12	Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2201.	7.4	9
13	Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. <i>Molecular Psychiatry</i> , 2021, 26, 2212-2223.	7.9	45
14	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	2.6	21
15	Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependence. <i>Addiction Biology</i> , 2021, 26, e12930.	2.6	4
16	Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 975-985.	4.7	15
17	Offering nicotine patches to all households in a community with high smoking rates: Pilot test of a population-based approach to promote tobacco cessation. <i>International Journal of Population Data Science</i> , 2021, 6, 1400.	0.1	2
18	Association of the Fatty Acid Amide Hydrolase C385A Polymorphism With Alcohol Use Severity and Coping Motives in Heavy-Drinking Youth. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 507-517.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Comparing the Rate of Nicotine Metabolism Among Smokers With Current or Past Major Depressive Disorder. <i>American Journal on Addictions</i> , 2021, 30, 382-388.	1.4	0
20	PharmVar GeneFocus: <i>CYP2B6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 82-97.	4.7	108
21	A Genome-Wide Association Study of Nausea Incidence in Varenicline-Treated Cigarette Smokers. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1805-1809.	2.6	3
22	The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization. <i>Psychopharmacology</i> , 2021, 238, 1791-1804.	3.1	7
23	Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 97-107.	1.5	6
24	Fatty acid amide hydrolase binding is inversely correlated with amygdalar functional connectivity: a combined positron emission tomography and magnetic resonance imaging study in healthy individuals. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E238-E246.	2.4	14
25	Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily Smokers. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1735-1743.	2.6	7
26	Use of electronic nicotine delivery systems (ENDS) among U.S. women of reproductive age: Prevalence, reported reasons for use, and toxin exposure. <i>Preventive Medicine</i> , 2021, 152, 106582.	3.4	4
27	Racial disparities in intensity of smoke exposure and nicotine intake among low-dependence smokers. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108641.	3.2	3
28	Sex Differences in the Association of Cigarette Craving With Insula Structure. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 624-633.	2.1	17
29	Functional connectivity of the anterior insula during withdrawal from cigarette smoking. <i>Neuropsychopharmacology</i> , 2021, 46, 2083-2089.	5.4	13
30	Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108708.	3.2	7
31	Use of additional nicotine replacement therapy by participants in a five-year follow-up of a tobacco cessation trial. <i>Addictive Behaviors</i> , 2021, 117, 106875.	3.0	0
32	The Role of Pharmacogenetics in Smoking. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 599-606.	4.7	13
33	Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet. <i>Advances in Nutrition</i> , 2021, 12, 2172-2189.	6.4	12
34	Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. <i>Molecular Neurobiology</i> , 2021, 58, 6540-6551.	4.0	7
35	Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke. <i>Clinical and Translational Science</i> , 2021, 14, 2474-2486.	3.1	2
36	Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. <i>Scientific Reports</i> , 2021, 11, 19572.	3.3	8

#	ARTICLE	IF	CITATIONS
37	The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. <i>Brain and Behavior</i> , 2021, 11, e01982.	2.2	6
38	Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV.. <i>Psychology of Addictive Behaviors</i> , 2021, 35, 788-796.	2.1	4
39	Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking. <i>Cancers</i> , 2021, 13, 5395.	3.7	2
40	Changes in Nicotine Metabolite Ratio Among Daily Smokers Receiving Treatment for Alcohol Use Disorder. <i>Nicotine and Tobacco Research</i> , 2020, 22, 256-263.	2.6	7
41	Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. <i>Addiction Biology</i> , 2020, 25, e12741.	2.6	25
42	Impact of early nausea on varenicline adherence and smoking cessation. <i>Addiction</i> , 2020, 115, 134-144.	3.3	14
43	Genome-Wide Meta-Analyses of FTND and TTFC Phenotypes. <i>Nicotine and Tobacco Research</i> , 2020, 22, 900-909.	2.6	17
44	Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. <i>Nicotine and Tobacco Research</i> , 2020, 22, 910-918.	2.6	14
45	Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1277-1284.	2.6	14
46	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 57-61.	4.7	42
47	Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6 transgenic mice: Effects on activity and drug responses. <i>British Journal of Pharmacology</i> , 2020, 177, 701-712.	5.4	11
48	D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction. <i>Neuropsychopharmacology</i> , 2020, 45, 745-752.	5.4	12
49	Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1419-1423.	2.6	3
50	The Influence of Tobacco Smoke/Nicotine on CYP2A Expression in Human and African Green Monkey Lungs. <i>Molecular Pharmacology</i> , 2020, 98, 658-668.	2.3	4
51	Addressing the instability issue of dopamine during microdialysis: the determination of dopamine, serotonin, methamphetamine and its metabolites in rat brain. <i>Journal of Chromatography A</i> , 2020, 1627, 461403.	3.7	19
52	Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice. <i>Molecular Neurobiology</i> , 2020, 57, 4608-4621.	4.0	5
53	Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. <i>Preventive Medicine</i> , 2020, 140, 106189.	3.4	6
54	Dissecting the genetic overlap of smoking behaviors, lung cancer, and chronic obstructive pulmonary disease: A focus on nicotinic receptors and nicotine metabolizing enzyme. <i>Genetic Epidemiology</i> , 2020, 44, 748-758.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Centrally administered CYP2D inhibitors increase oral tramadol analgesia in rats. <i>Brain Research Bulletin</i> , 2020, 164, 400-406.	3.0	4
56	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	1.3	18
57	Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice. <i>Molecular Neurobiology</i> , 2020, 57, 2509-2520.	4.0	9
58	Five-Year Follow-up of a Randomized Clinical Trial Testing Mailed Nicotine Patches to Promote Tobacco Cessation. <i>JAMA Internal Medicine</i> , 2020, 180, 792.	5.1	2
59	Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial. <i>Trials</i> , 2020, 21, 592.	1.6	2
60	Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. <i>Biology of Sex Differences</i> , 2020, 11, 8.	4.1	49
61	Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. <i>Neuropsychopharmacology</i> , 2020, 45, 1289-1296.	5.4	28
62	Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. <i>Drug and Alcohol Dependence</i> , 2020, 210, 107967.	3.2	1
63	Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1923-1927.	2.6	2
64	OpenVape: An Open-Source E-Cigarette Vapor Exposure Device for Rodents. <i>ENeuro</i> , 2020, 7, ENEURO.0279-20.2020.	1.9	24
65	Genetics of smoking behavior in American Indians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, cebp.0026.2020.	2.5	3
66	Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. <i>Journal of the National Medical Association</i> , 2019, 111, 509-520.	0.8	7
67	A Physiological Marriage Made in Heaven: Treating and Measuring the Brain Through Stimulation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 691-695.	4.7	2
68	Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107474.	3.2	5
69	C57BL/6 Substrain Differences in Pharmacological Effects after Acute and Repeated Nicotine Administration. <i>Brain Sciences</i> , 2019, 9, 244.	2.3	22
70	Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial. <i>Free Radical Biology and Medicine</i> , 2019, 143, 471-481.	2.9	36
71	Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1078-1087.	6.3	52
72	Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e36-e40.	2.1	13

#	ARTICLE	IF	CITATIONS
73	Attitudes toward Precision Treatment of Smoking in the Southern Community Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1345-1352.	2.5	11
74	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz-Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	4.7	125
75	Pharmacogenetics and Smoking Cessation. , 2019, , 499-507.		0
76	Evaluating metronidazole as a novel, safe <i>CYP2A6</i> phenotyping probe in healthy adults. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 960-969.	2.4	4
77	The Late Positive Potentials Evoked by Cigarette-Related and Emotional Images Show no Gender Differences in Smokers. <i>Scientific Reports</i> , 2019, 9, 3240.	3.3	5
78	Impact of Menthol on Oral Nicotine Consumption in Female and Male Sprague Dawley Rats. <i>Nicotine and Tobacco Research</i> , 2019, 22, 196-203.	2.6	13
79	Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans. <i>Data in Brief</i> , 2019, 27, 104787.	1.0	8
80	Differences in the rate of nicotine metabolism among smokers with and without HIV. <i>Aids</i> , 2019, 33, 1083-1088.	2.2	36
81	Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1706-1710.	2.6	17
82	Epigenome-wide association study of serum cotinine in current smokers reveals novel genetically driven loci. <i>Clinical Epigenetics</i> , 2019, 11, 1.	4.1	116
83	Neural basis of smoking-induced relief of craving and negative affect: Contribution of nicotine. <i>Addiction Biology</i> , 2019, 24, 1087-1095.	2.6	22
84	Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 641-651.	4.7	28
85	Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. <i>Addiction</i> , 2019, 114, 304-314.	3.3	12
86	Rat brain <i>CYP2D</i> activity alters <i>in vivo</i> central oxycodone metabolism, levels and resulting analgesia. <i>Addiction Biology</i> , 2019, 24, 228-238.	2.6	14
87	Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. <i>Psychology of Addictive Behaviors</i> , 2019, 33, 105-116.	2.1	45
88	Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 503-512.	2.1	9
89	Novel <i>CYP2A6</i> diplotypes identified through next-generation sequencing are associated with <i>in-vitro</i> and <i>in-vivo</i> nicotine metabolism. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 7-16.	1.5	20
90	Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. <i>Trends in Molecular Medicine</i> , 2018, 24, 187-196.	6.7	20

#	ARTICLE	IF	CITATIONS
91	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. <i>Nicotine and Tobacco Research</i> , 2018, 20, 403-413.	2.6	16
92	Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. <i>Nicotine and Tobacco Research</i> , 2018, 20, 414-424.	2.6	15
93	Effects of varenicline on cognitive function in non-smokers with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 562-563.	2.0	6
94	Relationships Between Smoking Behaviors and Cotinine Levels Among Two American Indian Populations With Distinct Smoking Patterns. <i>Nicotine and Tobacco Research</i> , 2018, 20, 466-473.	2.6	11
95	Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1489-1496.	2.6	17
96	CYP-mediated drug metabolism in the brain impacts drug response. , 2018, 184, 189-200.		59
97	Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers. <i>Psychopharmacology</i> , 2018, 235, 193-202.	3.1	46
98	Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. <i>Addiction</i> , 2018, 113, 509-523.	3.3	45
99	Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017). <i>Addictive Behaviors</i> , 2018, 79, 14-16.	3.0	4
100	Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 238-245.	2.5	24
101	Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers. <i>JAMA Network Open</i> , 2018, 1, e181346.	5.9	20
102	A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 882-891.	2.5	13
103	Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes. <i>Drug and Alcohol Dependence</i> , 2018, 190, 72-81.	3.2	11
104	The association between self-reported varenicline adherence and varenicline blood levels in a sample of cancer patients receiving treatment for tobacco dependence. <i>Addictive Behaviors Reports</i> , 2018, 8, 46-50.	1.9	4
105	Long-term effectiveness of mailed nicotine replacement therapy: study protocol of a randomized controlled trial 5-year follow-up. <i>BMC Public Health</i> , 2018, 18, 28.	2.9	7
106	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. <i>Nature Communications</i> , 2018, 9, 3221.	12.8	60
107	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 371-379.	2.5	9
108	Beyond Quitting: Any Additional Impact of Mailing Free Nicotine Patches to Current Smokers?. <i>Nicotine and Tobacco Research</i> , 2018, 20, 654-655.	2.6	6

#	ARTICLE	IF	CITATIONS
109	Opioids: The Painful Public Health Reality. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 924-935.	4.7	5
110	Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum. <i>Addiction</i> , 2018, 113, 2087-2096.	3.3	17
111	Functional Connectivity of the Raphe Nuclei: Link to Tobacco Withdrawal in Smokers. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 800-808.	2.1	11
112	Brain CYP2B induction can decrease nicotine levels in the brain. <i>Addiction Biology</i> , 2017, 22, 1257-1266.	2.6	8
113	The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA 2 analysis with dihydro- β -erythroidine. <i>Neuropharmacology</i> , 2017, 116, 9-17.	4.1	8
114	Designer Drugs 2.0. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 152-157.	4.7	10
115	Reduced-Nicotine Cigarettes in Young Smokers: Impact of Nicotine Metabolism on Nicotine Dose Effects. <i>Neuropsychopharmacology</i> , 2017, 42, 1610-1618.	5.4	31
116	Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 169-178.	1.5	22
117	Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 78, 140-148.	4.8	27
118	Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 143-154.	1.5	18
119	Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?. <i>Journal of Smoking Cessation</i> , 2017, 12, 63-70.	1.0	23
120	Does coffee consumption impact on heaviness of smoking?. <i>Addiction</i> , 2017, 112, 1842-1853.	3.3	13
121	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017, 49, 1126-1132.	21.4	472
122	Impact of self-reported lifetime depression or anxiety on effectiveness of mass distribution of nicotine patches. <i>Tobacco Control</i> , 2017, 26, 526-533.	3.2	1
123	Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 129-139.	2.5	31
124	Inducing rat brain CYP2D with nicotine increases the rate of codeine tolerance; predicting the rate of tolerance from acute analgesic response. <i>Biochemical Pharmacology</i> , 2017, 145, 158-168.	4.4	16
125	Measures and predictors of varenicline adherence in the treatment of nicotine dependence. <i>Addictive Behaviors</i> , 2017, 75, 122-129.	3.0	31
126	CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol. <i>Food Chemistry</i> , 2017, 217, 716-725.	8.2	27

#	ARTICLE	IF	CITATIONS
127	CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. <i>Biological Psychiatry</i> , 2017, 81, 554-563.	1.3	35
128	Pharmacogenetic Optimization of Smoking Cessation Treatment. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 55-66.	8.7	35
129	Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 230-234.	2.0	4
130	Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. <i>Scientific Reports</i> , 2017, 7, 17613.	3.3	15
131	Variation in CYP2A6 Activity and Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2017, 7, 18.	2.5	99
132	Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation?. <i>Experimental and Clinical Psychopharmacology</i> , 2017, 25, 216-222.	1.8	9
133	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [¹¹ C]CURB. <i>Biological Psychiatry</i> , 2016, 80, 691-701.	1.3	53
134	Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. <i>Pharmacogenomics</i> , 2016, 17, 405-415.	1.3	16
135	Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. <i>Drug and Alcohol Dependence</i> , 2016, 158, 139-146.	3.2	18
136	Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trial. <i>American Journal on Addictions</i> , 2016, 25, 291-296.	1.4	22
137	Genetic Relationship between Schizophrenia and Nicotine Dependence. <i>Scientific Reports</i> , 2016, 6, 25671.	3.3	67
138	Disposition kinetics and metabolism of nicotine and cotinine in African American smokers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 340-350.	1.5	30
139	Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2. <i>Scientific Reports</i> , 2016, 6, 20092.	3.3	42
140	The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. <i>Nicotine and Tobacco Research</i> , 2016, 18, 491-495.	2.6	24
141	Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 1-7.	2.9	51
142	A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2016, 47, 12-21.	1.8	15
143	Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers. <i>JAMA Internal Medicine</i> , 2016, 176, 184.	5.1	41
144	Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. <i>Biological Psychiatry</i> , 2016, 80, 190-197.	1.3	27

#	ARTICLE	IF	CITATIONS
145	<i>CYP2A6</i> genotyping methods and strategies using real-time and end point PCR platforms. <i>Pharmacogenomics</i> , 2016, 17, 147-162.	1.3	20
146	Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [11C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2016, 41, 1513-1520.	5.4	18
147	The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence. <i>Journal of Pediatric Biochemistry</i> , 2015, 01, 105-123.	0.2	8
148	RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. <i>BMC Genomics</i> , 2015, 16, 990.	2.8	28
149	Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. <i>PLoS ONE</i> , 2015, 10, e0126113.	2.5	20
150	A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. <i>PLoS Genetics</i> , 2015, 11, e1005498.	3.5	107
151	Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. <i>PLoS ONE</i> , 2015, 10, e0128109.	2.5	40
152	Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. <i>PLoS ONE</i> , 2015, 10, e0137070.	2.5	71
153	Pharmacogenetics of Nicotine and Associated Smoking Behaviors. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 23, 37-86.	1.7	42
154	Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. <i>International Journal of Epidemiology</i> , 2015, 44, 1537-1546.	1.9	62
155	Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1724-1729.	5.0	27
156	Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. <i>Neuropsychopharmacology</i> , 2015, 40, 1910-1918.	5.4	23
157	Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 131-138.	10.7	247
158	<i>UGT1A</i> and <i>UGT2B</i> Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 94-104.	2.5	27
159	Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1167-1172.	2.6	20
160	Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. <i>Neuropsychopharmacology</i> , 2015, 40, 1804-1812.	5.4	38
161	Rate of Nicotine Metabolism and Smoking Cessation Outcomes in a Community-based Sample of Treatment-Seeking Smokers. <i>Addictive Behaviors</i> , 2015, 51, 93-99.	3.0	45
162	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1239-1246.	2.5	65

#	ARTICLE	IF	CITATIONS
163	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [¹¹ C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1237-1240.	4.3	58
164	Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1505-1509.	2.6	17
165	Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 263-269.	1.5	25
166	CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers—findings from two independent populations. <i>Carcinogenesis</i> , 2015, 36, 99-103.	2.8	41
167	Cannabinoids: Friend or foe?. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 528-531.	4.7	8
168	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	1.2	341
169	Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1773-1782.	2.5	101
170	Nicotine Pharmacokinetics in Rats Is Altered as a Function of Age, Impacting the Interpretation of Animal Model Data. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1447-1455.	3.3	53
171	Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1971-1977.	3.3	24
172	Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 256-265.	4.7	49
173	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1638-1646.	2.6	21
174	Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 172-176.	1.5	17
175	Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 118-128.	1.5	29
176	Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. <i>Nicotine and Tobacco Research</i> , 2014, 16, 18-25.	2.6	22
177	Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. <i>Drug and Alcohol Dependence</i> , 2014, 138, 109-117.	3.2	13
178	The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. <i>Psychopharmacology</i> , 2014, 231, 2515-2523.	3.1	55
179	Ethanol self-administration and nicotine treatment increase brain levels of CYP2D6 in African green monkeys. <i>British Journal of Pharmacology</i> , 2014, 171, 3077-3088.	5.4	24
180	Rational design of novel CYP2A6 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6655-6664.	3.0	12

#	ARTICLE	IF	CITATIONS
181	Intracerebroventricularly and Systemically Delivered Inhibitor of Brain CYP2B (C8-Xanthate), Even Following Chlorpyrifos Exposure, Reduces Chlorpyrifos Activation and Toxicity in Male Rats. <i>Toxicological Sciences</i> , 2014, 140, 49-60.	3.1	13
182	Effect of food training and training dose on nicotine self-administration in rats. <i>Behavioural Brain Research</i> , 2014, 274, 10-18.	2.2	18
183	Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. <i>Neuropharmacology</i> , 2014, 85, 67-72.	4.1	28
184	Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. <i>Neuropharmacology</i> , 2013, 72, 74-81.	4.1	23
185	Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. <i>Addiction</i> , 2013, 108, 2202-2211.	3.3	30
186	Factors Associated with Discontinuation of Bupropion and Counseling Among African American Light Smokers in a Randomized Clinical Trial. <i>Annals of Behavioral Medicine</i> , 2013, 46, 336-348.	2.9	15
187	Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. <i>Addictive Behaviors</i> , 2013, 38, 1796-1803.	3.0	33
188	First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. <i>Biochemical Pharmacology</i> , 2013, 85, 1848-1855.	4.4	35
189	Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. <i>Development (Cambridge)</i> , 2013, 140, 3285-3296.	2.5	138
190	Nicotine-motivated behavior in <i>C. elegans</i> requires the nicotinic acetylcholine receptor subunits $\alpha 5$ and $\alpha 15$. <i>European Journal of Neuroscience</i> , 2013, 37, 743-756.	2.6	24
191	Infusion of brain-derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation. <i>European Journal of Neuroscience</i> , 2013, 37, 996-1003.	2.6	18
192	Dose-independent kinetics with low level exposure to nicotine and cotinine. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 277-279.	2.4	3
193	Potential role of CYP2D6 in the central nervous system. <i>Xenobiotica</i> , 2013, 43, 973-984.	1.1	58
194	Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls. <i>Neuropsychopharmacology</i> , 2013, 38, 2327-2337.	5.4	17
195	$CHRNA5$ - $AB4$ genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. <i>Addiction</i> , 2013, 108, 1818-1828.	3.3	16
196	High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine: A Proof of Concept Placebo-Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2013, 15, 348-354.	2.6	27
197	Effect of a Nicotine Vaccine on Nicotine Binding to $\alpha 2$ -Nicotinic Acetylcholine Receptors In Vivo in Human Tobacco Smokers. <i>American Journal of Psychiatry</i> , 2013, 170, 399-407.	7.2	44
198	Cytochrome P450-mediated drug metabolism in the brain. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 152-163.	2.4	103

#	ARTICLE	IF	CITATIONS
199	Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2013, 14, 8381-8392.	4.1	12
200	Imaging Changes in Synaptic Acetylcholine Availability in Living Human Subjects. <i>Journal of Nuclear Medicine</i> , 2013, 54, 78-82.	5.0	33
201	Tobacco Use Among Southwestern Alaska Native People. <i>Nicotine and Tobacco Research</i> , 2013, 15, 401-406.	2.6	17
202	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. <i>Carcinogenesis</i> , 2013, 34, 93-101.	2.8	45
203	Nicotine Kinetics in Zebra Finches In Vivo and In Vitro. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1240-1246.	3.3	3
204	The DRD4 Exon III VNTR, Bupropion, and Associations With Prospective Abstinence. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1190-1200.	2.6	18
205	The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 708-718.	2.5	77
206	Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 135-141.	1.5	55
207	CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 232-235.	1.5	58
208	Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 94-103.	1.5	85
209	Variation in Trans-3- β -Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. <i>PLoS ONE</i> , 2013, 8, e70938.	2.5	39
210	Rat Brain CYP2B-Enzymatic Activation of Chlorpyrifos to the Oxon Mediates Cholinergic Neurotoxicity. <i>Toxicological Sciences</i> , 2012, 126, 325-335.	3.1	51
211	Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1105-1114.	2.5	96
212	Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 290-298.	6.3	74
213	Exposure to Nicotine and Carcinogens among Southwestern Alaskan Native Cigarette Smokers and Smokeless Tobacco Users. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 934-942.	2.5	32
214	DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 551-554.	1.5	8
215	CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 429-440.	1.5	39
216	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 695-708.	1.5	114

#	ARTICLE	IF	CITATIONS
217	Twenty-First-Century Neuroscience: The Potential for Innovative Therapies for Brain Disorders. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 153-157.	4.7	2
218	The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. <i>Neurobiology of Aging</i> , 2012, 33, 2160-2171.	3.1	68
219	CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 771-777.	4.7	72
220	Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. <i>NeuroImage</i> , 2012, 60, 2136-2143.	4.2	45
221	Developmental Hippocampal Neuroplasticity in a Model of Nicotine Replacement Therapy during Pregnancy and Breastfeeding. <i>PLoS ONE</i> , 2012, 7, e37219.	2.5	18
222	Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers. <i>Annals of Behavioral Medicine</i> , 2012, 43, 253-261.	2.9	11
223	CYP2A6 genetic variation and dexmedetomidine disposition. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 937-942.	1.9	42
224	Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects. <i>Neuropsychopharmacology</i> , 2011, 36, 692-700.	5.4	44
225	Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 708-714.	8.7	205
226	Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health. <i>Addiction</i> , 2011, 106, 689-697.	3.3	4
227	Associations of CYP2A6 genotype with smoking behaviors in southern China. <i>Addiction</i> , 2011, 106, 985-994.	3.3	46
228	Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. <i>BMC Public Health</i> , 2011, 11, 741.	2.9	16
229	Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. <i>Trials</i> , 2011, 12, 22.	1.6	21
230	Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 234-238.	2.5	101
231	Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. <i>European Journal of Endocrinology</i> , 2011, 165, 961-967.	3.7	29
232	Relationship Between CYP2A6 and CHRNA5-CHRNA3-CHRNA4 Variation and Smoking Behaviors and Lung Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1342-1346.	6.3	168
233	Association of the Nicotine Metabolite Ratio and CHRNA5/CHRNA3 Polymorphisms With Smoking Rate Among Treatment-Seeking Smokers. <i>Nicotine and Tobacco Research</i> , 2011, 13, 498-503.	2.6	23
234	Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 239-251.	1.9	55

#	ARTICLE	IF	CITATIONS
235	Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. <i>Brain Research</i> , 2010, 1348, 1-9.	2.2	19
236	Effect of metabolic blockade on the psychoactive effects of dextromethorphan. <i>Human Psychopharmacology</i> , 2010, 25, 71-79.	1.5	23
237	Neurodegenerative Diseases: A Growing Challenge. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 427-430.	4.7	8
238	Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. <i>European Journal of Neuroscience</i> , 2010, 31, 1185-1193.	2.6	59
239	Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. <i>Xenobiotica</i> , 2010, 40, 381-392.	1.1	46
240	Dopaminergic Signaling Mediates the Motivational Response Underlying the Opponent Process to Chronic but Not Acute Nicotine. <i>Neuropsychopharmacology</i> , 2010, 35, 943-954.	5.4	38
241	New CYP2A6 gene deletion and conversion variants in a population of Black African descent. <i>Pharmacogenomics</i> , 2010, 11, 189-198.	1.3	31
242	Pharmacogenetics of Drug Dependence: Role of Gene Variations in Susceptibility and Treatment. <i>Annual Review of Pharmacology and Toxicology</i> , 2010, 50, 39-61.	9.4	34
243	Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. <i>Addiction Science & Clinical Practice</i> , 2010, 5, 17-29.	2.6	25
244	Utility and Relationships of Biomarkers of Smoking in African-American Light Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 3426-3434.	2.5	31
245	A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. <i>Pharmacogenomics Journal</i> , 2009, 9, 274-282.	2.0	37
246	Dopamine Genes and Nicotine Dependence in Treatment-Seeking and Community Smokers. <i>Neuropsychopharmacology</i> , 2009, 34, 2252-2264.	5.4	41
247	Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 6-11.	2.9	200
248	Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. <i>European Journal of Pharmacology</i> , 2009, 609, 88-95.	3.5	26
249	Brain and Disease: The Long Path to Discovery and Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 343-346.	4.7	0
250	Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African-American Light Smokers. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 635-643.	4.7	146
251	Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition. <i>Neuropsychopharmacology</i> , 2009, 34, 634-640.	5.4	52
252	Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes. <i>Journal of Neurogenetics</i> , 2009, 23, 252-261.	1.4	111

#	ARTICLE	IF	CITATIONS
253	Genetic and environmental influences on the ratio of 3- α -hydroxycotinine to cotinine in plasma and urine. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 388-398.	1.5	72
254	A systems biology network model for genetic association studies of nicotine addiction and treatment. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 538-551.	1.5	22
255	Molecular Genetics of Nicotine Metabolism. <i>Handbook of Experimental Pharmacology</i> , 2009, , 235-259.	1.8	52
256	Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. <i>Psychopharmacology</i> , 2008, 198, 181-190.	3.1	52
257	Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. <i>Human Mutation</i> , 2008, 29, 679-688.	2.5	69
258	Drug Addiction: A Critical Problem Calling for Novel Solutions. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 503-506.	4.7	2
259	Identification of Novel CYP2A6*1B Variants: The CYP2A6*1B Allele is Associated With Faster In Vivo Nicotine Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 115-121.	4.7	48
260	Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. <i>Neuropharmacology</i> , 2008, 55, 1147-1155.	4.1	72
261	Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1319-1325.	2.6	7
262	Selegiline Is a Mechanism-Based Inactivator of CYP2A6 Inhibiting Nicotine Metabolism in Humans and Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 992-999.	2.5	41
263	Nicotinic acetylcholine receptor $\alpha 2$ subunit gene implicated in a systems-based candidate gene study of smoking cessation. <i>Human Molecular Genetics</i> , 2008, 17, 2834-2848.	2.9	129
264	A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 67-75.	1.5	50
265	Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 54-63.	2.4	46
266	Non-Nicotinic Therapies for Smoking Cessation. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 541-564.	9.4	69
267	CYP2B6 Genotype Does Not Alter Nicotine Metabolism, Plasma Levels, or Abstinence with Nicotine Replacement Therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1312-1314.	2.5	42
268	The Role of CYP2A6 in the Emergence of Nicotine Dependence in Adolescents. <i>Pediatrics</i> , 2007, 119, e264-e274.	2.1	125
269	Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA/2 and C57BL/6 Mice. <i>Molecular Pharmacology</i> , 2007, 71, 826-834.	2.3	80
270	An association of CYP2A6 genotype and smoking topography. <i>Nicotine and Tobacco Research</i> , 2007, 9, 511-518.	2.6	78

#	ARTICLE	IF	CITATIONS
271	Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 1007-1015.	1.5	36
272	Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. <i>Drug and Alcohol Dependence</i> , 2007, 89, 24-33.	3.2	66
273	Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. <i>Pharmacogenomics</i> , 2007, 8, 1385-1402.	1.3	100
274	Differences in pharmacogenetics of nicotine and alcohol metabolism: Review and recommendations for future research. <i>Nicotine and Tobacco Research</i> , 2007, 9, 459-474.	2.6	20
275	CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial. <i>Biological Psychiatry</i> , 2007, 62, 635-641.	1.3	124
276	The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 660-666.	1.7	97
277	Guidelines on nicotine dose selection for in vivo research. <i>Psychopharmacology</i> , 2007, 190, 269-319.	3.1	694
278	CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. <i>Neuropharmacology</i> , 2006, 50, 441-450.	4.1	42
279	Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. <i>Neuropharmacology</i> , 2006, 50, 568-575.	4.1	42
280	INDUCTION AND RECOVERY TIME COURSE OF RAT BRAIN CYP2E1 AFTER NICOTINE TREATMENT. <i>Drug Metabolism and Disposition</i> , 2006, 34, 647-652.	3.3	44
281	Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. <i>Journal of Neurochemistry</i> , 2006, 96, 1028-1041.	3.9	41
282	Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. <i>Journal of Neurochemistry</i> , 2006, 98, 1866-1875.	3.9	113
283	Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. <i>British Journal of Pharmacology</i> , 2006, 148, 786-794.	5.4	17
284	Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 600-608.	4.7	242
285	CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 457-467.	4.7	184
286	Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 481-484.	1.9	21
287	Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. <i>Psychopharmacology</i> , 2006, 184, 401-408.	3.1	71
288	Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. <i>European Journal of Pharmacology</i> , 2006, 552, 151-158.	3.5	14

#	ARTICLE	IF	CITATIONS
289	In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1508-1515.	3.3	21
290	Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. <i>Journal of Psychopharmacology</i> , 2006, 20, 7-14.	4.0	20
291	CYP2A6 Genotype, Phenotype, and the Use of Nicotine Metabolites as Biomarkers during Ad libitum Smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1812-1819.	2.5	57
292	Genetic Influences on Smoking. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 704-709.	2.0	21
293	Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 189-192.	1.5	37
294	Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 115-125.	1.5	68
295	Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 145-158.	4.7	231
296	Nicotine physical dependence and tolerance in the mouse following chronic oral administration. <i>Psychopharmacology</i> , 2005, 178, 183-192.	3.1	79
297	HUMAN CYP2D6 AND MOUSE CYP2D5: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1495-1502.	3.3	45
298	Evidence of Association between Smoking and $\alpha 7$ Nicotinic Receptor Subunit Gene in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2004, 29, 1522-1526.	5.4	129
299	Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. <i>International Journal of Epidemiology</i> , 2004, 33, 971-978.	1.9	96
300	The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics. <i>Drug Metabolism Reviews</i> , 2004, 36, 313-333.	3.6	124
301	Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 64-72.	4.7	366
302	Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 615-626.	5.7	279
303	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. <i>Twin Research and Human Genetics</i> , 2004, 7, 435-448.	1.0	37
304	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. <i>Twin Research and Human Genetics</i> , 2004, 7, 435-448.	1.0	2
305	Decreasing smoking behaviour and risk through CYP2A6 inhibition. <i>Drug Discovery Today</i> , 2003, 8, 487-493.	6.4	72
306	Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. <i>British Journal of Pharmacology</i> , 2003, 138, 1376-1386.	5.4	119

#	ARTICLE	IF	CITATIONS
307	Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. <i>Neuropharmacology</i> , 2003, 45, 122-132.	4.1	188
308	Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2003, 1619, 283-290.	2.4	55
309	Nicotine-dependence symptoms are associated with smoking frequency in adolescents. <i>American Journal of Preventive Medicine</i> , 2003, 25, 219-225.	3.0	236
310	Rat Hepatic CYP2E1 Is Induced by Very Low Nicotine Doses: An Investigation of Induction, Time Course, Dose Response, and Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 941-947.	2.5	42
311	Down-Regulation of Hepatic Nicotine Metabolism and a CYP2A6-Like Enzyme in African Green Monkeys after Long-Term Nicotine Administration. <i>Molecular Pharmacology</i> , 2003, 63, 96-104.	2.3	57
312	The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. <i>Nicotine and Tobacco Research</i> , 2003, 5, 891-899.	2.6	59
313	INTERACTION OF BUPRENORPHINE AND ITS METABOLITE NORBUPRENORPHINE WITH CYTOCHROMES P450 IN VITRO. <i>Drug Metabolism and Disposition</i> , 2003, 31, 768-772.	3.3	51
314	Genetics of alcohol and tobacco use in humans. <i>Annals of Medicine</i> , 2003, 35, 94-121.	3.8	206
315	CYP2E1*1D regulatory polymorphism. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 321-328.	5.7	50
316	CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 321-8.	5.7	21
317	Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. <i>Nicotine and Tobacco Research</i> , 2002, 4, 423-431.	2.6	49
318	Metabolism of 18-Methoxycoronaridine, an Ibogaine Analog, to 18-Hydroxycoronaridine by Genetically Variable CYP2C19. <i>Drug Metabolism and Disposition</i> , 2002, 30, 663-669.	3.3	19
319	The role of pharmacogenetically-variable cytochrome P450 enzymes in. <i>Pharmacogenomics</i> , 2002, 3, 185-199.	1.3	53
320	Treatment of Codeine Dependence With Inhibitors of Cytochrome P450 2D6. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 326-329.	1.4	23
321	Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 163-171.	2.0	118
322	Designer Drugs That Are Potent Inhibitors of CYP2D6. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 330-332.	1.4	12
323	Genotyping human CYP2A6 variants. <i>Methods in Enzymology</i> , 2002, 357, 59-69.	1.0	26
324	Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives. <i>Drug Metabolism and Disposition</i> , 2002, 30, 314-318.	3.3	223

#	ARTICLE	IF	CITATIONS
325	CYP2A6 genetic variation and potential consequences. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1245-1256.	13.7	118
326	Reduced ($\hat{\pm}$)-3,4-methylenedioxymethamphetamine ($\hat{\epsilon}$ Ecstasy $\hat{\epsilon}$) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , 2002, 63, 2111-2119.	4.4	57
327	Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. <i>Journal of Neurochemistry</i> , 2002, 82, 1376-1387.	3.9	129
328	Drug-metabolizing cytochrome P450s in the brain. <i>Journal of Psychiatry and Neuroscience</i> , 2002, 27, 406-15.	2.4	120
329	Chapter 8 Ibogaine in the treatment of heroin withdrawal. <i>The Alkaloids Chemistry and Biology</i> , 2001, 56, 155-171.	2.0	71
330	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. <i>Canadian Journal of Physiology and Pharmacology</i> , 2001, 79, 841-847.	1.4	57
331	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 477-487.	5.7	90
332	Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 85-94.	5.7	47
333	Altered GABA _A Receptor Subunit and Splice Variant Expression in Rats Treated With Chronic Intermittent Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 819-828.	2.4	48
334	Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain Abbreviations: CYP, cytochrome P450; C8 xanthate, potassium octylxanthate; NCO, nicotine C-oxidation; NDMA, N-nitrosodimethylamine; NMA, N-nitroso-N-methylaniline; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; and SSC, saline-sodium citrate buffer.. <i>Biochemical Pharmacology</i> , 2001, 62, 1025-1036.	4.4	33
335	Deficient C-oxidation of nicotine continued. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 567-567.	4.7	11
336	Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures. <i>Annals of the New York Academy of Sciences</i> , 2000, 914, 394-401.	3.8	106
337	Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. <i>Biochemical Pharmacology</i> , 2000, 59, 1501-1511.	4.4	113
338	Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 35-43.	4.7	146
339	Duplications and Defects in the <i>CYP2A6</i> Gene: Identification, Genotyping, and In Vivo Effects on Smoking. <i>Molecular Pharmacology</i> , 2000, 58, 747-755.	2.3	222
340	The influence of an endogenous $\hat{2}$ 3 subunit on recombinant GABA _A receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. <i>Neuropharmacology</i> , 2000, 39, 611-620.	4.1	22
341	Mimicking Gene Defects to Treat Drug Dependence. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 233-246.	3.8	40
342	Cytochrome P450 2D6 and Treatment of Codeine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 43-45.	1.4	27

#	ARTICLE	IF	CITATIONS
343	Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 435-444.	1.4	46
344	A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. <i>Nicotine and Tobacco Research</i> , 1999, 1, 63-67.	2.6	31
345	Differences in propensity for drinking alcohol are reflected in subunit- and region-specific GABAA receptor levels. <i>Addiction Biology</i> , 1999, 4, 309-316.	2.6	4
346	Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 472-475.	1.4	28
347	Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 378-383.	4.7	38
348	Nicotine metabolism defect reduces smoking. <i>Nature</i> , 1998, 393, 750-750.	27.8	359
349	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 305-313.	5.7	82
350	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 325-333.	5.7	85
351	Psychotropic Effects of Dextromethorphan Are Altered by the CYP2D6 Polymorphism. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 332-337.	1.4	46
352	CYP2D6 phenotype and genotype in a Canadian native indian population. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 145-148.	5.7	20
353	Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 375-379.	5.7	131
354	Intercellular Calcium Waves in Neurons. <i>Molecular and Cellular Neurosciences</i> , 1996, 7, 337-353.	2.2	95
355	The Human Dopamine D5 Receptor Gene: Cloning and Characterization of the 5'-Flanking and Promoter Region. <i>Biochemistry</i> , 1995, 34, 5960-5970.	2.5	65
356	A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. <i>Nature</i> , 1993, 364, 448-450.	27.8	114
357	Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. <i>Pharmacogenetics and Genomics</i> , 1991, 1, 26-32.	5.7	152
358	The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [3H]GBR-12935 binding proteins. <i>Archives of Biochemistry and Biophysics</i> , 1990, 276, 424-432.	3.0	203
359	Modifying the Metabolism of Nicotine as a Therapeutic Strategy. <i>Novartis Foundation Symposium</i> , 0, , 235-248.	1.1	0
360	Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. <i>Nicotine and Tobacco Research</i> , 0, , .	2.6	1